SGMO vs. IRWD, EBS, CDXS, RIGL, XOMA, VNDA, VSTM, LXRX, ACHV, and RGLS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs.
Sangamo Therapeutics (NASDAQ:SGMO) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.
Sangamo Therapeutics has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sangamo Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 404.59%. Ironwood Pharmaceuticals has a consensus price target of $10.40, suggesting a potential upside of 184.15%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Ironwood Pharmaceuticals.
In the previous week, Ironwood Pharmaceuticals had 8 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 1 mentions for Sangamo Therapeutics. Ironwood Pharmaceuticals' average media sentiment score of 0.80 beat Sangamo Therapeutics' score of 0.11 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.
Ironwood Pharmaceuticals has a net margin of -0.65% compared to Sangamo Therapeutics' net margin of -257.87%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Sangamo Therapeutics' return on equity.
56.9% of Sangamo Therapeutics shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 12.9% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Sangamo Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.
Ironwood Pharmaceuticals received 57 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. However, 62.66% of users gave Sangamo Therapeutics an outperform vote while only 61.08% of users gave Ironwood Pharmaceuticals an outperform vote.
Summary
Ironwood Pharmaceuticals beats Sangamo Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 1/18/2025 by MarketBeat.com Staff
Free SGMO Stock Alerts